Core Viewpoint - Novo Nordisk is set to launch the Wegovy pill, which offers a significant first-mover advantage in the oral GLP-1 market, ahead of Eli Lilly's version [1][2]. Group 1: Product Launch and Efficacy - The Wegovy pill is expected to be available in January, while Eli Lilly's version will not be released until March, providing Novo Nordisk with a head start [2]. - The Wegovy pill demonstrates an efficacy of 17% for regular users, with one in three users potentially achieving up to 20% weight loss [3]. - This product allows patients to choose between an injection and a pill without compromising on efficacy, marking a significant advancement in treatment options [5]. Group 2: Competitive Strategy - Novo Nordisk emphasizes that there are no other Phase III trials of oral GLP-1s that have shown comparable efficacy to Wegovy [4]. - The company plans to leverage its extensive safety data accumulated over more than 10 years to support the Wegovy pill's market success [5]. - The Wegovy pill not only aids in weight loss but also provides cardiovascular protection, enhancing its appeal to patients [6].